CRISPR/Cas9 genome editing system and its application in tumor therapy

doi:10.3760/cma.j.issn.1673-422X.2018.09.010

Abstract

Abstract: CRISPR/Cas9 gene editing system is a new tool of gene editing technology based on the immune mechanism of archaea against foreign nucleic acid invasion. Due to its high efficiency and accuracy, CRISPR/Cas9 genome editing technology has been widely used in tumor therapeutic research, such as targeted knockout of oncogenes, repair of tumor suppressor genes, breaking immune tolerance, and construction of tumor models, which brings revolutionary development to tumor gene therapy.

Key words: Neoplasms, Therapeutic uses, CRISPR/Cas9 genome editing technique

Yang Yehuan, Yang Chengwei, Tan Xiaoqing, Gao Xingchun. CRISPR/Cas9 genome editing system and its application in tumor therapy[J]. Journal of International Oncology, 2018, 45(8): 556-560.

References

［1］ Ul Ain Q, Chung JY, Kim YH. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN［J］. J Control Release, 2015, 205: 120127. DOI: 10.1016/j.jconrel.2014.12.036. ［2］ Mojica FJ, DiezVillasenor C, Soria E, et al. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria［J］. Mol Microbiol, 2000, 36(1): 244246. ［3］ Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes［J］. Science, 2007, 315(5819): 17091712. DOI: 10.1126/science.1138140. ［4］ Mojica FJ, DiezVillasenor C, GarciaMartinez J, et al. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements［J］. J Mol Evol, 2005, 60(2): 174182. DOI: 10.1007/s0023900400463. ［5］ Brouns SJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes［J］. Science, 2008, 321(5891): 960964. DOI: 10.1126/science.1159689. ［6］ Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA［J］. Science, 2008, 322(5909): 18431845. DOI: 10.1126/science.1165771. ［7］ Deveau H, Barrangou R, Garneau JE, et al. Phage response to CRISPRencoded resistance in Streptococcus thermophilus［J］. J Bacteriol, 2008, 190(4): 13901400. DOI: 10.1128/JB.0141207. ［8］ Shen J, Lv L, Wang X, et al. Comparative analysis of CRISPRCas systems in Klebsiella genomes［J］. J Basic Microbiol, 2017, 57(4): 325336. DOI: 10.1002/jobm.201600589. ［9］ Guan L, Han Y, Zhu S, et al. Application of CRISPRCas system in gene therapy: preclinical progress in animal model［J］. DNA Repair (Amst), 2016, 46: 18. DOI: 10.1016/j.dnarep.2016.07.004. ［10］ Makarova KS, Wolf YI, Alkhnbashi OS, et al. An updated evolutionary classification of CRISPRCas systems［J］. Nat Rev Microbiol, 2015, 13(11): 722736. DOI: 10.1038/nrmicro3569. ［11］杨帆, 李寅. 新一代基因组编辑系统CRISPR/Cpf1［J］. 生物工程学报, 2017, 33(3): 361371. DOI: 10.13345/j.cjb.170029. ［12］ Kunin V, Sorek R, Hugenholtz P. Evolutionary conservation of sequence and secondary structures in CRISPR repeats［J］. Genome Biol, 2007, 8(4): R61. DOI: 10.1186/gb200784r61. ［13］ Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes［J］. Science, 2007, 315(5819): 17091712. DOI: 10.1126/science.1138140. ［14］杨悦, 訾晓渊, 孙颖浩. CRISPRCas基因编辑技术在泌尿系统肿瘤研究中的应用［J］. 中国肿瘤生物治疗杂志, 2018, 25(1): 916. DOI: 10.3872/j.issn.1007385X.2018.01.002. ［15］ Li Y, Ma S, Sun L, et al. Programmable single and multiplex baseediting in bombyx mori using RNAguided cytidine deaminases［J］. G3 (Bethesda), 2018, 8(5): 17011709. DOI: 10.1534/g3.118.200134. ［16］ White MK, Khalili K. CRISPR/Cas9 and cancer targets: future possibilities and present challenges［J］. Oncotarget, 2016, 7(11): 1230512317. DOI: 10.18632/oncotarget.7104. ［17］孟泽松, 王飞飞, 王光林, 等. CRISPR/Cas9基因编辑技术在肿瘤研究及治疗中的应用［J］. 肿瘤, 2016, 36(5): 13951401. DOI: 10.3781/j.issn.10007431.2016.55.514. ［18］ Hu Z, Yu L, Zhu D, et al. Disruption of HPV16E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells［J］. Biomed Res Int, 2014, 2014: 612823. DOI: 10.1155/2014/612823. ［19］ Zhen S, Li X. Oncogenic human papillomavirus: application of CRISPR/Cas9 therapeutic strategies for cervical cancer［J］. Cell Physiol Biochem, 2017, 44(6): 24552466. DOI: 10.1159/000486168. ［20］ Noguchi T, Ward JP, Gubin MM, et al. Temporally distinct PDL1 expression by tumor and host cells contributes to immune escape［J］. Cancer Immunol Res, 2017, 5(2): 106117. DOI: 10.1158/23266066.CIR160391. ［21］ Su S, Hu B, Shao J, et al. CRISPRCas9 mediated efficient PD1 disruption on human primary T cells from cancer patients［J］. Sci Rep, 2016, 6: 20070. DOI: 10.1038/srep20070. ［22］ Kalebic N, Taverna E, Tavano S, et al. CRISPR/Cas9induced disruption of gene expression in mouse embryonic brain and single neural stem cells in vivo［J］. EMBO Rep, 2016, 17(3): 338348. DOI: 10.15252/embr.201541715. ［23］ Li L, Hu S, Chen X. Nonviral delivery systems for CRISPR/Cas9based genome editing: challenges and opportunities［J］. Biomaterials, 2018, 171: 207218. DOI: 10.1016/j.biomaterials.2018.04.031. ［24］ Kulcsár PI, Tálas A, Huszár K, et al. Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage［J］. Genome Biol, 2017, 18(1): 190. DOI: 10.1186/s1305901713188. ［25］ Chen JS, Dagdas YS, Kleinstiver BP, et al. Enhanced proofreading governs CRISPRCas9 targeting accuracy［J］. Nature, 2017, 550(7676): 407410. DOI: 10.1038/nature24268. ［26］ Cox DBT, Gootenberg JS, Abudayyeh OO, et al. RNA editing with CRISPRCas13［J］. Science, 2017, 358(6366): 10191027. DOI: 10.1126/science.aaq0180.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.